Bone Index announced that the Food and Drug Administration (FDA) has granted clearance for the second generation Bindex device model to aid in the diagnosis of osteoporosis.

Bindex is a point-of-care device that measures the cortical bone thickness of the tibia. Its algorithm then calculates the Density Index, which estimates bone mineral density at the hip as measured with DXA scan. 

Bindex is able to detect osteoporosis with 90% specificity and sensitivity and has proven to be an accurate instrument in diagnosing osteoporosis and evidence-based treatment decisions. This allows the identification of a patients at risk for osteoporosis before the occurrence of a first bone fracture.

Continue Reading

Bindex provides results in 30 seconds allowing physicians to do more screenings and to prescribe necessary treatment. The device is plugged in a USB port and can be carried around to each patient.

The first generation Bindex device model was initially cleared by the FDA in May 2016.

Related Articles


Bone Index receives FDA 510(k) clearance for the second generation Bindex® point-of-care device to help physicians in diagnosing osteoporosis. Published online January 20, 2017. Accessed January 20, 2017.

follow @RheumAdvisor

This article originally appeared on MPR